Aspirin desensitization in patients with AERD
- PMID: 12668896
- DOI: 10.1385/CRIAI:24:2:159
Aspirin desensitization in patients with AERD
Abstract
All patients with aspirin exacerbated respiratory disease (AERD) can be desensitized to ASA. After achieving this state, patients can then take ASA daily without adverse effect. ASA desensitization can be maintained indefinitely as long as the patient takes ASA each day. Crossdesensitization with older NSAIDs also occurs. After ASA desensitization, patients can take daily ASA in order to treat their underlying respiratory disease. In AERD patients treated with ASA 650 BID for at least a year, 115/172 (67%) improved in their clinical courses while decreasing systemic and topical corticosteroids. Sixteen failed to improve, 24 stopped ASA because of intractable side effects (gastritis or hives) and 17 patients discontinued ASA treatment in the first year of study for unrelated reasons. Therefore, treatment with daily ASA is a significant therapeutic option for patients afflicted with AERD. It should be used for AERD patients who do not respond to topical corticosteroids and leukotriene modifier drugs. Those who respond to systemic steroids or have intractable or recurrent nasal polyps are particularly well-suited for this therapeutic intervention.
Similar articles
-
Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs.Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. doi: 10.1007/s11882-004-0037-x. Curr Allergy Asthma Rep. 2004. PMID: 14680616 Review.
-
Failure of tacrolimus to prevent aspirin-induced respiratory reactions in patients with aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2005 Oct;116(4):755-60. doi: 10.1016/j.jaci.2005.05.020. Epub 2005 Jul 21. J Allergy Clin Immunol. 2005. PMID: 16210047 Clinical Trial.
-
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease.Am J Rhinol Allergy. 2018 Jul;32(4):280-286. doi: 10.1177/1945892418770260. Epub 2018 Apr 23. Am J Rhinol Allergy. 2018. PMID: 29682983
-
[Long-term efficacy of aspirin desensitization in aspirin-exacerbated respiratory disease. Review of two clinical cases].Rev Alerg Mex. 2016 Apr-Jun;63(2):207-12. doi: 10.29262/ram.v63i2.151. Rev Alerg Mex. 2016. PMID: 27174764 Spanish.
-
Prevention and treatment of reactions to NSAIDs.Clin Rev Allergy Immunol. 2003 Apr;24(2):189-98. doi: 10.1385/CRIAI:24:2:189. Clin Rev Allergy Immunol. 2003. PMID: 12668898 Review.
Cited by
-
Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease.J Allergy Clin Immunol. 2016 Oct;138(4):1089-1097.e3. doi: 10.1016/j.jaci.2016.04.042. Epub 2016 Jun 14. J Allergy Clin Immunol. 2016. PMID: 27423494 Free PMC article.
-
Primary Cutaneous Vasculitis Masquerading as Drug Induced following Aspirin Desensitization.Case Rep Med. 2013;2013:745714. doi: 10.1155/2013/745714. Epub 2013 Nov 24. Case Rep Med. 2013. PMID: 24348575 Free PMC article.
-
Appraisal of the Real-World Effectiveness of Biologic Therapies in Aspirin-Exacerbated Respiratory Disease.J Allergy Clin Immunol Pract. 2022 Feb;10(2):478-484.e3. doi: 10.1016/j.jaip.2021.09.030. Epub 2021 Sep 28. J Allergy Clin Immunol Pract. 2022. PMID: 34597850 Free PMC article.
-
Pharmacological management of nasal polyposis.Drugs. 2005;65(11):1537-52. doi: 10.2165/00003495-200565110-00006. Drugs. 2005. PMID: 16033291 Review.
-
Vascular endothelial growth factor drives autocrine epithelial cell proliferation and survival in chronic rhinosinusitis with nasal polyposis.Am J Respir Crit Care Med. 2009 Dec 1;180(11):1056-67. doi: 10.1164/rccm.200905-0740OC. Epub 2009 Sep 17. Am J Respir Crit Care Med. 2009. PMID: 19762561 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical